Top Markets
Coin of the day
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
株式のランク #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
株価
$0.02653368
時価総額
$150.29K
変化(1日)
-4.41%
変化(1年)
194.29%
GB
取引 Genflow Biosciences Plc (GENF)

カテゴリー

Genflow Biosciences Plc(GENF)のEPS
2026 時点のEPS TTM: 0
Genflow Biosciences Plcの最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Genflow Biosciences PlcのEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS